



ASX Announcement

5 November 2020

Lapse of Unlisted Share Options

Invion Limited (ASX:IVX) wishes to advise that on 30 October 2020 the following unlisted share options have lapsed with the resignation of Craig Newton as Managing Director and CEO.

Lapsed Options	Exercise Price	Expiry Date
27,257,615	\$0.0300	12/02/2023
4,088,642	\$0.0200	30/10/2023
4,088,642	\$0.0106	31/10/2024

The number of options on hand following the lapse of the above options are as follows:

*ASX security code and description	*Total number of +securities on issue
IVXAS UNL OPT @ \$0.0175 Exp 18/11/2020	5,000
IVXAT OPT @ \$0.03 Exp 12/02/2023	207,612,166
IVXAU OPT @ \$0.02 Exp 30/10/2023	2,725,761
IVXAV OPT @ \$0.0172 Exp 31/08/2024	20,443,211
IVXAAA OPT @ \$0.02 Exp 01/07/2024	15,928,570
IVXAY OPT @ \$0.0177 Exp 22/10/2024	20,443,211
IVXAW OPT @ \$0.00 Exp 31/10/2024	5,689,623
IVXAZ OPT @ \$0.0106 Exp 31/10/2024	2,725,762

Investor enquiries

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Media enquires

Brendon Lau

T: 0409 341 613

E: brendon@vantagepointpartners.com.au



About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by a Sub-Committee of the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.